Selurampanel
![]() | |
Systematic (IUPAC) name | |
---|---|
N-[7-Isopropyl-6-(2-methylpyrazol-3-yl)-2,4-dioxo-1H-quinazolin-3-yl]methanesulfonamide | |
Identifiers | |
CAS Number | 912574-69-7 |
ATC code | None |
PubChem | CID 45381907 |
ChemSpider | 32698379 |
Chemical data | |
Formula | C16H19N5O4S |
Molar mass | 377.418 g/mol |
| |
|
Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy.[1][2][3] It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.[4]
See also
References
- ↑ Faught, Edward (2014). "BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy". Expert Opinion on Investigational Drugs 23 (1): 107–113. doi:10.1517/13543784.2014.848854. ISSN 1354-3784.
- ↑ Belcastro, Vincenzo; Verrotti, Alberto (2015). "Novel Molecular Targets for Drug-Treatment of Epilepsy": 183–199. doi:10.1007/978-3-319-12283-0_10.
- ↑ Hanada, Takahisa (2014). "The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence". Journal of Receptor, Ligand and Channel Research: 39. doi:10.2147/JRLCR.S51475. ISSN 1178-699X.
- ↑ Gomez-Mancilla B, Brand R, Jürgens TP, et al. (February 2014). "Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks". Cephalalgia 34 (2): 103–13. doi:10.1177/0333102413499648. PMID 23963355.
|
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.